Возможности терапии при заболеваниях спектра оптиконевромиелита
https://doi.org/10.17650/2073-8803-2021-16-4-49-58
Аннотация
Заболевания спектра оптиконевромиелита – редкие хронические аутоиммунные воспалительные демиелинизирующие заболевания центральной нервной системы. Учитывая, что нарастание неврологического дефицита при заболеваниях спектра оптиконевромиелита обусловлено преимущественно повторяющимися обострениями, задачи фармакотерапии включают купирование рецидивов и предупреждение их развития. Информация о показаниях к назначению терапии и потенциальных побочных эффектах препаратов необходима для четкой оценки потенциальных преимуществ и рисков для пациентов с заболеваниями спектра оптиконевромиелита в каждом индивидуальном случае.
Ключевые слова
заболевания спектра оптиконевромиелита,
антитела к миелинолигодендроцитарному гликопротеину,
антитела к аквапорину 4,
интерлейкин 6,
анти-В-клеточная терапия
При поддержке: Статья подготовлена при поддержке компании Roche.
Об авторе
Е. С. Новикова
ГБУЗ МО «Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского»
Россия
Россия
Екатерина Сергеевна Новикова
129110 Москва, ул. Щепкина, 61/2
Список литературы
1. Бойко А.Н., Смирнова Н.Ф., Щукин И.А. и др. Офатумумаб – новый препарат для лечения рассеянного склероза. Журнал неврологии и психиатрии им. С.С. Корсакова 2021;121(7 вып. 2):1–8.
2. Котов А.С., Новикова Е.С., Меткечекова Ю.В. Клинический полиморфизм демиелинизирующих заболеваний, ассоциированных с антителами к MOG. Журнал неврологии и психиатрии им. С.С. Корсакова 2020;120(12):95–101.
3. Котов С.В., Новикова Е.С., Котов А.С. Анти-В-клеточная терапия у пациентов с заболеваниями спектра оптиконевромиелита. Неврология, нейропсихиатрия, психосоматика 2021;13(4):18–24.
4. Симанив Т.О., Васильев А.В., Аскарова Л.Ш., Захарова М.Н. Оптикомиелит и заболевания спектра оптиконейромиелита. Журнал неврологии и психиатрии им. С.С. Корсакова 2019;119(10 вып. 2):35–48.
5. Araki M., Aranami T., Matsuoka T. et al. Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab. Mod Rheumatol 2013;23:827–31. DOI:10.1007/s10165-012-0715-9.
6. Asseyer S., Cooper G., Paul F. Pain in NMOSD and MOGAD: a systematic literature review of pathophysiology, symptoms and current treatment strategies. Front Neurol 2020;11:778. DOI:10.3389/fneur.2020.00778.
7. Asseyer S., Schmidt F., Chien C. et al. Pain in AQP4-IgG-positive and MOGIgG-positive neuromyelitis optica spectrum disorders. Mult Scler J Exp Transl Clin 2018;4(3):2055217318796684. DOI:10.1177/2055217318796684.
8. Ataie-Kachoie P., Pourgholami M.H., Morris D.L. Inhibition of the IL-6 signaling pathway: a strategy to combat chronic inflammatory diseases and cancer. Cytokine Growth Factor Rev 2013;24:163–73. DOI:10.1371/journal.pone.0060817.
9. Ayzenberg I., Kleiter I., Schröder A., Hellwig K. el al. Interleukin 6 receptor blockade in patients with neuromyelitis optica non responsive to anti-CD20 therapy. JAMA Neurol 2013;70:394–7. DOI:10.1001/jamaneurol.2013.1246.
10. Baker D., Pryce G., James L.K. et al. The ocrelizumab phase II extension trial suggests the potential to improve the risk: Benefit balance in multiple sclerosis. Mult Scler Relat Disord 2020;44:102279. DOI:10.1016/j.msard.2020.102279.
11. Beekman J., Keisler A., Pedraza O. et al. Neuromyelitis optica spectrum disorder: patient experience and quality of life. Neurol Neuroimmunol Neuroinflamm 2019;6(4):e580. DOI:10.1212/NXI.0000000000000580.
12. Bennett J.L., O’Connor K.C., Bar-Or A. et al. B lymphocytes in neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm 2015;2(3):1–11. DOI:10.1212/NXI.0000000000000104.
13. Braun N., Risler T. Immunoadsorption as a tool for the immunomodulation of the humoral and cellular immune system in autoimmune disease. Ther Apher 1999;3:240–5. DOI:10.1046/j.1526-0968.1999.00155.x.
14. Chavarro V.S., Mealy M.A., Simpson A. et al. Insufficient treatment of severe depression in neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflamm 2016;e286. DOI:10.1212/NXI.0000000000000286.
15. Ciron J., Audoin B., Bourre B. et al. Recommendations for the use of Rituximab in neuromyelitis optica spectrum disorders. Rev Neurol 2018;174(4):255–64. DOI:10.1016/j.neurol.2017.11.005.
16. Collongues N., Brassat D., Maillart E. et al. Efficacy of rituximab in refractory neuromyelitis optica. Mult Scler J 2016;22:955–9. DOI:10.1177/1352458515602337.
17. Cree B.A., Bennett J.L., Kim H.J. et al. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. Lancet 2019;394:1352–63. DOI:10.1016/S0140-6736(19)31817-3.
18. Damato V., Evoli A., Iorio R. Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis. JAMA Neurol 2016;73:1342–8. DOI:10.1001/jamaneurol.2016.1637.
19. De Souza Moraes A., Brum D.G., Ierich J.C. et al. A highly specific and sensitive nanoimmunosensor for the diagnosis of neuromyelitis optica spectrum disorders. Scientific Rep 2019;9(1):1–9. DOI:10.1038/s41598-019-52506-w.
20. Dienz O., Eaton S.M., Bond J.P. et al. The induction of antibody production by IL-6 is indirectly mediated by IL-21 produced by CD4+ T cells. J Exp Med 2009;206:69–78. DOI:10.1038/s41598-019-52506-w.
21. Espiritu A.I. Efficacy and tolerability of azathioprine for neuromyelitis optica spectrum disorder: A systematic review and meta-analysis. Mult Scler Rel Disord 2019;33:22–32. DOI:10.1016/j.msard.2019.05.011.
22. Forsthuber T.G., Cimbora D.M., Ratchford J.N. et al. B cell-based therapies in CNS autoimmunity: differentiating CD19 and CD20 as therapeutic targets. Ther Adv Neurol Disord 2018;11:175628641876169. DOI:10.1177/1756286418761697.
23. Frampton J.E. Eculizumab: A review in neuromyelitis optica spectrum disorder. Drugs 2020;80(7):719–27. DOI:10.1007/s40265-020-01297-w.
24. Fryer J.P., Lennon V.A., Pittock S.J. et al. AQP4 autoantibody assay performance in clinical laboratory service. Neurol Neuroimmunol Neuroinflamm 2014;1(1). DOI:10.1212/NXI.0000000000000011.
25. Gao Y., Zhang B., Yang J. Satralizumab for the treatment of neuromyelitis optica spectrum disorders. Ann Pharmacother 2021;55(9):1167–71. DOI:10.1177/1060028020976669.
26. Hinson S.R., McKeon A., Fryer J.P. et al. Prediction of neuromyelitis optica attack severity by quantitation of complementmediated injury to aquaporin4expressing cells. Arch Neurol 2009;66:1164–67. DOI:10.1001/archneurol.2009.188.
27. Icoz S., Tuzun E., Kurtuncu M. et al. Enhanced IL-6 production in aquaporin-4 anti-body positive neuromyelitis optica patients. Int J Neurosci 2010;120:71–5. DOI:10.3109/00207450903428970.
28. Jacob A., Weinshenker B.G., Violich I. et al. Treatment of neuromyelitis optica with rituximab: Retrospective analysis of 25 patients. Arch Neurol 2008;65:1443–8. DOI:10.1001/archneur.65.11.noc80069.
29. Kim S.H., Kim W., Li X.F. et al. Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years. Arch Neurol 2011;68:1412–20. DOI:10.1001/archneurol.2011.154.
30. Kimbrough D., Fujihara K., Jacob A. et al. Treatment of neuromyelitis optica: Review and recommendations. Mult Scler Relat Disord 2012;1:180–7. DOI:10.1016/j.msard.2012.06.002.
31. Kitley J., Waters P., Woodhall M. et al. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies. JAMA Neurol 2014;71(3):276. DOI:10.1001/jamaneurol.2013.5857.
32. Lee C., Ka-Fung H., Chiu P. et al. Differential brainstem atrophy patterns in multiple sclerosis and neuromyelitis optica spectrum disorders. J Magn Reson Imaging 2017;47(6):1601–9. DOI:10.1002/jmri.25866.
33. Lennon V.A., Wingerchuk D.M., Kryzer T.J. et al. A serum autoantibody marker of neuromyelitisoptica: distinction from multiple sclerosis. Lancet 2004;364:2106–12. DOI:10.1016/S0140-6736(04)17551-X.
34. Levy M., Fujihara K., Palace J. New therapies for neuromyelitis optica spectrum disorder. Lancet Neurol 2021;1:60–7. DOI:10.1016/S1474-4422(20)30392-6.
35. Lunemann J., Nimmerjahn F., Dalakas M.C. Intravenous immunoglobulin in neurology. Mode of action and clinical efficacy. Nat Rev Neurol 2015;11:80–9. DOI:10.1038/nrneurol.2014.253.
36. Matsushita T., Tateishi T., Isobe N. et al. Characteristic cerebrospinal fluid cytokine/chemokine profiles in neuromyelitis optica relapsing remitting or primary progressive multiple sclerosis. PLoS One 2013;8:e61835. DOI:10.1371/journal.pone.0061835.
37. Nakamura M., Nakazawa T., Doi H. et al. Early high-dose intravenous methylprednisolone is effective in preserving retinal nerve fiber layer thickness in patients with neuromyelitis optica. Graefe’s Arch Clin Exp Ophthalmol 2010;248: 1777–85. DOI:10.1007/s00417-010-1344-7.
38. Palanichamy A., Jahn S., Nickles D. et al. Rituximab efficiently depletes increased CD20-expressing T cells in multiple sclerosis patients. J Immunol 2014;193:580–6. DOI:10.4049/jimmunol.1400118.
39. Pellkofer H.L., Krumbholz M., Berthele A. et al. Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. Neurology 2011;76:1310–5. DOI:10.1212/WNL.0b013e3182152881.
40. Salama S., Khan M., Pardo S. et al. MOG antibody–associated encephalomyelitis/encephalitis. Mult Scler J 2019;25(11):1427–33. DOI:10.1177/1352458519837705.
41. Sato D.K., Nakashima I., Takahashi T. et al. Aquaporin-4 antibody-positive cases beyond current diagnostic criteria for NMO spectrum disorders. Neurology 2013;80(24):2210–6. DOI:10.1212/WNL.0b013e318296ea08.
42. Schuh E., Berer K., Mulazzani M. et al. Features of human CD3+CD20+ T cells. J Immunol 2016;197:1111–7. DOI:10.4049/jimmunol.1400118.
43. Sellner J., Boggild M., Clanet M. et al. EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol 2010;17:1019–32. DOI:10.1038/s41598-019-52506-w.
44. Stiebel-Kalish H., Hellmann M.A., Mimouni M. et al. Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optica neuritis? Neurol Neuroimmunol Neuroinflamm 2019;6:e572. DOI:10.1212/NXI.0000000000000572.
45. Traboulsee A., Greenberg B.M., Bennett J.L. et al. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: A randomized, double-blind, multicenter, placebo-controlled phase 3 trial. Lancet Neurol 2020;19:402–12. DOI:10.1016/S1474-4422(20)30078-8.
46. Tradtrantip L., Felix C.M., Spirig R. et al. Recombinant IgG1 Fc hexamers block cytotoxicity and pathological changes in experimental in vitro and rat models of neuromyelitis optica. Neuropharmacology 2018;133:345–53. DOI:10.1016/j.neuropharm.2018.02.002.
47. Trebst C., Jarius S., Berthele A. et al. Update on the diagnosis and treatment of neuromyelitis optica: Recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol 2014;261:1–16. DOI:10.1007/s00415-013-7169-7.
48. Uchida T., Mori M., Uzawa A. et al. Increased cerebrospinal fluid metalloproteinase-2 and interleukin-6 are associated with albumin quotient in neuromyelitis optica: their possible role on blood-brain barrier disruption. Mult Scler 2017;23:1072–84. DOI:10.1177/1352458516672015.
49. Uzawa A., Mori M., Arai K. et al. Cytokine and chemokine profiles in neuromyelitis optica: significance of interleukin-6. Mult Scler 2010;16:1443–52. DOI:10.1177/1352458510379247.
50. Uzawa A., Mori M., Masuda H. et al. Interleukin-6 analysis of 572 consecutive CSF samples from neurological disorders: a special focus on neuromyelitis optica. Clin Chim Acta 2017;469:144–9. DOI:10.1016/j.cca.2017.03.006.
51. Wallach A.I., Tremblay M., Kister I. Advances in the treatment of neuromyelitis optica spectrum disorder. Neurol Clin 2021;39(1):35–49. DOI:10.1016/j.ncl.2020.09.003.
52. Wang H.H., Dai Y.Q., Qiu W. et al. Interleukin-17-secreting T cells in neuromyelitis optica and multiple sclerosis during relapse. J Clin Neurosci 2011;18:1313–7. DOI:10.1016/j.jocn.2011.01.031.
53. Weber M.S., Derfuss T., Metz I., Brück W. Defining distinct features of anti-MOG antibody associated central nervous system demyelination. Therc Adv Neurol Disord. 2018;11:1756286418762083. DOI:110.1177/1756286418762083.
54. Wingerchuk D.M., Banwell B., Bennett J.L. et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015;85:177–89. DOI:10.1212/WNL.0000000000001729.
55. Wingerchuk D.M., Lennon V.A., Pittock S.J. et. al. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006;66:1485–9. DOI:10.1212/01.wnl.0000216139.44259.74.
56. Yamamura T., Kleiter I., Fujihara K. et al. Trial of satralizumab in neuromyelitis optica spectrum disorder. N Engl J Med 2019;381:2114–24. DOI:10.1056/NEJMoa1901747.
57. Yang C.S., Yang L., Li T. et al. Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis optica. Neurology 2013;81:710–3. DOI:10.1212/WNL.0b013e3182a1aac7.
58. Yao X., Verkman A.S. Complement regulator CD59 prevents peripheral organ injury in rats made seropositive for neuromyelitis optica immunoglobulin G. Acta Neuropathol Commun 2017;5:57. DOI:10.1186/s40478-017-0462-4.
Рецензия
Для цитирования:
Новикова Е.С. Возможности терапии при заболеваниях спектра оптиконевромиелита. Русский журнал детской неврологии. 2021;16(4):49-58. https://doi.org/10.17650/2073-8803-2021-16-4-49-58
For citation:
Novikova E.S. Possibilities of therapy for neuromyelitis optica spectrum disorders. Russian Journal of Child Neurology. 2021;16(4):49-58. (In Russ.) https://doi.org/10.17650/2073-8803-2021-16-4-49-58
Просмотров:
575
Послать статью по эл. почте 